This press release contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Alexion, including statements related to: the potential benefits of SOLIRIS as a treatment for adult patients with anti-aquaporin 4 (AQP4) antibody positive neuromyelitis optica
spectrum disorder (NMOSD) and the potential impact of SOLIRIS on the NMOSD community; the ability of SOLIRIS to change the treatment paradigm for NMOSD and that SOLIRIS can provide benefits for patients with NMOSD.
Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica
spectrum disorder: findings from the PREVENT study.
TM has a number of different causes including multiple sclerosis (MS), neuromyelitis optica
, and in association with connective tissue diseases, such as systemic lupus erythematosus and Sjogren's syndrome.
International consensus diagnostic criteria for neuromyelitis optica
Benjamin Greenberg, who leads the Conquer programs at UT Southwestern, including the Transverse Myelitis and Neuromyelitis Optica
Program and the Pediatric Conquer Program at Children's Medical Center Dallas.
As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS) and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG), and is also developing it for patients with neuromyelitis optica
spectrum disorder (NMOSD).
In 10-50% of patients with neuromyelitis optica
(NMO) spectrum disease, anti-aquaporin 4 (anti-AQP4) antibody is observed to be negative (1).
Brain MRI showed abnormal signals along the bottom of the fourth ventricle which was typically seen in neuromyelitis optica
(NMO) and in the cerebellum.
OKLAHOMA CITY Oklahoma Medical Research Foundation scientist Bob Axtell, Ph.D., has received a four-year grant from the National Institutes of Health to study a rare autoimmune disease called neuromyelitis optica
, or NMO.
Inebilzumab is being evaluated for the treatment of neuromyelitis optica
, a rare condition affecting the optic nerve and spinal cord and is in Phase II study.
It has been found that cetirizine - common allergy medication - is safe, well-tolerated, and may reduce relapses in patients with neuromyelitis optica